G. J. Filheiro

Predictors of four versus six cycles of adjuvant docetaxel–cyclophosphamide in hormone receptor-positive early breast cancer

Introduction: Docetaxel and cyclophosphamide (TC) are a commonly used anthracycline-free regimen for hormone receptor-positive (HR+) early-stage breast cancer. Although typically administered for four to six cycles, the optimal number remains uncertain. Objective: To identify clinical and pathological factors associat...